Partially  	Partially  	 RB	O
hydrolysed  	hydrolysed  	 CD	B-NP
100 	100 	 CD	O
%  	%  	 NN	O
whey-based  	whey-based  	 JJ	O
infant  	infant  	 NN	O
formula  	formula  	 NN	O
and  	and  	 CC	O
the  	the  	 DT	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
atopic  	atopic  	 JJ	B-NP
dermatitis 	dermatitis 	 NN	I-NP
:  	:  	 :	O
comparative  	comparative  	 FW	B-NP
pharmacoeconomic  	pharmacoeconomic  	 FW	I-NP
analyses  	analyses  	 FW	I-NP
Clinical  	Clinical  	 FW	I-NP
trials  	trials  	 NNS	I-NP
have  	have  	 VBP	O
demonstrated  	demonstrated  	 VBN	O
that  	that  	 IN	O
the  	the  	 DT	O
risk  	risk  	 NN	O
of  	of  	 IN	O
developing  	developing  	 VBG	O
atopic  	atopic  	 JJ	B-NP
dermatitis  	dermatitis  	 NN	I-NP
is  	is  	 VBZ	O
reduced  	reduced  	 VBN	O
when  	when  	 WRB	O
using  	using  	 VBG	O
hydrolysed  	hydrolysed  	 JJ	B-NP
formulas  	formulas  	 NNS	I-NP
to  	to  	 TO	O
feed  	feed  	 VB	O
infants  	infants  	 NNS	O
with  	with  	 IN	O
a  	a  	 DT	O
documented  	documented  	 JJ	O
risk  	risk  	 NN	O
of  	of  	 IN	O
atopy  	atopy  	 NNS	B-NP
( 	( 	 -LRB-	O
i.e.  	i.e.  	 FW	O
an  	an  	 DT	O
affected  	affected  	 JJ	O
parent  	parent  	 NN	O
and 	and 	 CC	O
/ 	/ 	 NNP	O
or  	or  	 CC	O
sibling 	sibling 	 CD	B-NP
) 	) 	 -RRB-	I-NP
when  	when  	 WRB	I-NP
breastfeeding  	breastfeeding  	 NN	I-NP
is  	is  	 VBZ	O
not  	not  	 RB	O
practised 	practised 	 VBN	O
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
little  	little  	 RB	O
is  	is  	 VBZ	O
known  	known  	 VBN	O
about  	about  	 IN	O
the  	the  	 DT	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	O
using  	using  	 VBG	O
hydrolysed  	hydrolysed  	 JJ	B-NP
formulas 	formulas 	 NNS	I-NP
.  	.  	 .	O
Consequently 	Consequently 	 RB	O
,  	,  	 ,	O
economic  	economic  	 JJ	B-NP
analyses  	analyses  	 NNS	I-NP
in  	in  	 IN	O
5  	5  	 CD	O
European  	European  	 JJ	O
countries  	countries  	 NNS	O
( 	( 	 -LRB-	O
Denmark 	Denmark 	 NNP	O
,  	,  	 ,	O
France 	France 	 NNP	O
,  	,  	 ,	O
Germany 	Germany 	 NNP	O
,  	,  	 ,	O
Spain  	Spain  	 NNP	O
and  	and  	 CC	O
Switzerland 	Switzerland 	 NNP	B-NP
)  	)  	 -RRB-	O
have  	have  	 VBP	O
evaluated  	evaluated  	 VBN	O
the  	the  	 DT	O
costs  	costs  	 NNS	O
and  	and  	 CC	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	O
a  	a  	 DT	O
specific  	specific  	 JJ	O
brand  	brand  	 NN	O
of  	of  	 IN	O
100 	100 	 CD	O
%  	%  	 NN	O
whey-based  	whey-based  	 NN	O
partially  	partially  	 RB	O
hydrolysed  	hydrolysed  	 JJ	B-NP
infant  	infant  	 NN	I-NP
formula 	formula 	 NN	I-NP
,  	,  	 ,	O
NAN-HA®  	NAN-HA®  	 NNP	B-NP
( 	( 	 -LRB-	O
PHF-W 	PHF-W 	 NNP	B-NP
)  	)  	 -RRB-	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
cow 	cow 	 NN	O
's  	's  	 POS	O
milk  	milk  	 NN	O
standard  	standard  	 JJ	B-NP
formula  	formula  	 NN	I-NP
( 	( 	 -LRB-	O
SF 	SF 	 NNP	B-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
the  	the  	 DT	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
atopic  	atopic  	 JJ	B-NP
dermatitis  	dermatitis  	 NN	I-NP
in  	in  	 IN	O
at-risk  	at-risk  	 JJ	B-NP
children 	children 	 NNS	I-NP
.  	.  	 .	O
This  	This  	 DT	O
review  	review  	 NN	O
synthesises  	synthesises  	 VBD	O
the  	the  	 DT	O
findings  	findings  	 NNS	O
of  	of  	 IN	O
these  	these  	 DT	O
studies 	studies 	 NNS	O
.  	.  	 .	O
Cost-effectiveness  	Cost-effectiveness  	 JJ	B-NP
analyses  	analyses  	 NNS	I-NP
( 	( 	 -LRB-	O
CEA 	CEA 	 NNP	B-NP
)  	)  	 -RRB-	O
used  	used  	 VBD	O
a  	a  	 DT	O
decision-analytic  	decision-analytic  	 JJ	B-NP
model  	model  	 NN	I-NP
to  	to  	 TO	O
determine  	determine  	 VB	O
treatment  	treatment  	 NN	B-NP
pathways 	pathways 	 NN	I-NP
,  	,  	 ,	O
resource  	resource  	 JJ	B-NP
utilisation  	utilisation  	 NN	I-NP
and  	and  	 CC	O
costs  	costs  	 NNS	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
management  	management  	 NN	O
of  	of  	 IN	O
atopic  	atopic  	 JJ	B-NP
dermatitis  	dermatitis  	 NN	I-NP
in  	in  	 IN	O
healthy  	healthy  	 JJ	O
at-risk  	at-risk  	 JJ	B-NP
newborns  	newborns  	 NNS	I-NP
who  	who  	 WP	O
were  	were  	 VBD	O
not  	not  	 RB	O
exclusively  	exclusively  	 RB	O
breastfed 	breastfed 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
model  	model  	 NN	O
had  	had  	 VBD	O
a  	a  	 DT	O
12-month  	12-month  	 JJ	O
horizon  	horizon  	 NN	O
and  	and  	 CC	O
applied  	applied  	 VBD	B-NP
reimbursement  	reimbursement  	 JJ	I-NP
rates  	rates  	 NNS	I-NP
of  	of  	 IN	O
60-100 	60-100 	 CD	O
%  	%  	 NN	O
depending  	depending  	 VBG	O
on  	on  	 IN	O
the  	the  	 DT	O
country 	country 	 NN	O
.  	.  	 .	O
Outcomes  	Outcomes  	 NNP	O
were  	were  	 VBD	O
considered  	considered  	 VBN	O
from  	from  	 IN	O
the  	the  	 DT	O
perspective  	perspective  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
public  	public  	 JJ	B-NP
healthcare  	healthcare  	 JJ	I-NP
system  	system  	 NN	I-NP
( 	( 	 -LRB-	O
e.g.  	e.g.  	 CD	O
the  	the  	 DT	O
Ministry  	Ministry  	 NNP	O
of  	of  	 IN	O
Health 	Health 	 NNP	O
;  	;  	 :	O
MOH 	MOH 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
family  	family  	 NN	O
and  	and  	 CC	O
society 	society 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
final  	final  	 JJ	B-NP
outcome  	outcome  	 NN	I-NP
was  	was  	 VBD	O
the  	the  	 DT	O
incremental  	incremental  	 JJ	B-NP
cost-effectiveness  	cost-effectiveness  	 JJ	I-NP
ratio  	ratio  	 NN	I-NP
per  	per  	 IN	O
avoided  	avoided  	 JJ	O
case  	case  	 NN	O
of  	of  	 IN	O
atopic  	atopic  	 JJ	B-NP
dermatitis  	dermatitis  	 NNS	I-NP
( 	( 	 -LRB-	O
ICER 	ICER 	 NNP	B-NP
)  	)  	 -RRB-	O
for  	for  	 IN	O
PHF-W  	PHF-W  	 JJ	B-NP
versus  	versus  	 CC	O
SF 	SF 	 NNP	B-NP
.  	.  	 .	O
A  	A  	 DT	O
cost-minimisation  	cost-minimisation  	 JJ	B-NP
analysis  	analysis  	 NN	I-NP
was  	was  	 VBD	O
also  	also  	 RB	O
performed  	performed  	 VBN	O
to  	to  	 TO	O
compare  	compare  	 VB	O
PHF-W  	PHF-W  	 JJ	B-NP
with  	with  	 IN	O
extensively  	extensively  	 FW	B-NP
hydrolysed  	hydrolysed  	 FW	I-NP
formulas  	formulas  	 FW	I-NP
( 	( 	 -LRB-	O
EHF 	EHF 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
base-case  	base-case  	 JJ	B-NP
CEA  	CEA  	 NNP	I-NP
produced  	produced  	 VBD	O
ICERs  	ICERs  	 JJ	O
per  	per  	 IN	O
avoided  	avoided  	 JJ	O
case  	case  	 NN	O
for  	for  	 IN	O
PHF-W  	PHF-W  	 JJ	B-NP
versus  	versus  	 CC	O
SF  	SF  	 NNP	B-NP
of  	of  	 IN	I-NP
EUR  	EUR  	 NNP	I-NP
982-1,343  	982-1,343  	 NNP	O
( 	( 	 -LRB-	O
MOH  	MOH  	 NNP	B-NP
perspective 	perspective 	 NN	I-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
EUR  	EUR  	 NNP	B-NP
-2,202  	-2,202  	 NNP	O
to  	to  	 TO	O
-624  	-624  	 CD	O
( 	( 	 -LRB-	O
family  	family  	 NN	B-NP
perspective 	perspective 	 NN	I-NP
)  	)  	 -RRB-	O
indicating  	indicating  	 VBG	B-NP
savings 	savings 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
EUR  	EUR  	 NNP	B-NP
-1,220  	-1,220  	 NNP	O
to  	to  	 TO	O
719  	719  	 CD	O
from  	from  	 IN	O
the  	the  	 DT	O
societal  	societal  	 JJ	B-NP
perspective 	perspective 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
main  	main  	 JJ	O
costs  	costs  	 NNS	O
related  	related  	 VBN	O
to  	to  	 TO	O
formula  	formula  	 NN	O
( 	( 	 -LRB-	O
MOH  	MOH  	 NNP	B-NP
and  	and  	 CC	O
society 	society 	 NN	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
time  	time  	 NN	B-NP
loss  	loss  	 NN	I-NP
( 	( 	 -LRB-	O
family 	family 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
cost-minimisation  	cost-minimisation  	 JJ	B-NP
analysis 	analysis 	 NN	I-NP
,  	,  	 ,	O
PHF-W  	PHF-W  	 JJ	B-NP
yielded  	yielded  	 JJ	O
savings  	savings  	 NNS	O
of  	of  	 IN	O
between  	between  	 IN	O
EUR  	EUR  	 NNP	B-NP
4.3  	4.3  	 CD	O
and  	and  	 CC	O
120  	120  	 CD	O
million  	million  	 CD	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
EHF-whey  	EHF-whey  	 JJ	B-NP
when  	when  	 WRB	O
the  	the  	 DT	O
latter  	latter  	 NN	O
was  	was  	 VBD	O
used  	used  	 VBN	O
in  	in  	 IN	O
prevention 	prevention 	 NN	O
.  	.  	 .	O
In  	In  	 IN	O
conclusion 	conclusion 	 NN	O
,  	,  	 ,	O
PHF-W  	PHF-W  	 NNP	B-NP
was  	was  	 VBD	O
cost-effective  	cost-effective  	 JJ	O
versus  	versus  	 CC	O
SF  	SF  	 NNP	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
prevention  	prevention  	 NN	O
of  	of  	 IN	O
atopic  	atopic  	 JJ	B-NP
dermatitis  	dermatitis  	 NN	I-NP
and  	and  	 CC	O
cost  	cost  	 NN	O
saving  	saving  	 VBG	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
EHF  	EHF  	 NNP	B-NP
when  	when  	 WRB	O
used  	used  	 VBN	O
in  	in  	 IN	O
prevention 	prevention 	 NN	O
.  	.  	 .	O
